Productivity in biotech is a better problem to have than its opposite—but it's still a problem. Yet thanks to a variety of new project financing sources, and a particularly clever approach to marrying them with Big Pharma alliances, it is in fact possible to turn research productivity into a source of non-dilutive capital.
By mid- 2004, George Scangos, PhD realized his company was facing a major financing crunch. The CEO of Exelixis Inc....